(Q91891911)
Statements
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma (English)
Takashi Kumada
Masatoshi Kudo
Hidenori Toyoda
Toshifumi Tada
Masashi Hirooka
Toru Ishikawa
Koichi Takaguchi
Noritomo Shimada
Hironori Ochi
Akemi Tsutsui
Takuya Nagano
Norio Itokawa
Korenobu Hayama
Yohei Koizumi
Kojiro Michitaka
Atsushi Hiraoka
Kazuya Kariyama
Michitaka Imai
Masanori Atsukawa
Kazuhiro Nouso
Tsutomu Tamai
Yoichi Hiasa
Kunihiko Tsuji
Ei Itobayashi
Hiroshi Shibata
Hironori Tanaka
Real-life Practice Experts for HCC (RELPEC) Study Group
HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)